Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Raxibacumab> ?p ?o }
Showing triples 1 to 63 of
63
with 100 triples per page.
- Raxibacumab abstract "Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.Approval LetterThe antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences. Cambridge Antibody Technology discovered the antibody to Human Genome Sciences's target and, in 2012, HGS were purchased by GlaxoSmithKline.According to GSK \"Raxibacumab injection is a monoclonal antibody targeting the protective antigen (PA) component of the lethal toxin of Bacillus anthracis and is being developed for the treatment of inhalational anthrax. The most commonly observed adverse events were headaches, upper respiratory tract infection, nausea, pain in extremity (pain in limbs) and pruritus (skin itching). Local skin reaction in one study has led to the recommendation that an anti-histamine be administered prior to infusion.\"GSK go on to say \"Raxibacumab was developed by Human Genome Sciences (HGS) in conjunction with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS) under contract number HHS010020050006C. It is now part of GSK’s portfolio, following GSK’s acquisition of HGS in July 2012. The development of raxibacumab is the result of a coordinated response to a recognised public health threat and the US government’s request for new medical countermeasures in the event of an anthrax attack against the civilian population.\"At the 2 November 2012 meeting of the Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) members \"voted 16 to 1 in support of the clinical benefit of raxibacumab for the treatment of inhalational anthrax, with one abstention. In addition, the committee voted 18 – 0 in favour of the risk-benefit profile of raxibacumab\".In 2009, support from the FDA was denied after it \"expressed doubt on the agent's added benefit over the antibiotic levofloxacin (Levaquin) alone\".On Dec. 14, 2012, FDA approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.".
- Raxibacumab atcPrefix "J06".
- Raxibacumab atcSuffix "BB18".
- Raxibacumab casNumber "565451-13-0".
- Raxibacumab wikiPageExternalLink 125349Orig1s000ltr.pdf.
- Raxibacumab wikiPageID "9701593".
- Raxibacumab wikiPageLength "5419".
- Raxibacumab wikiPageOutDegree "10".
- Raxibacumab wikiPageRevisionID "707386024".
- Raxibacumab wikiPageWikiLink Anthrax.
- Raxibacumab wikiPageWikiLink Cambridge_Antibody_Technology.
- Raxibacumab wikiPageWikiLink Category:Monoclonal_antibodies.
- Raxibacumab wikiPageWikiLink GlaxoSmithKline.
- Raxibacumab wikiPageWikiLink Human.
- Raxibacumab wikiPageWikiLink Human_Genome_Sciences.
- Raxibacumab wikiPageWikiLink Monoclonal_antibody.
- Raxibacumab wikiPageWikiLink Preventive_healthcare.
- Raxibacumab wikiPageWikiLinkText "Raxibacumab".
- Raxibacumab wikiPageWikiLinkText "raxibacumab".
- Raxibacumab atcPrefix "J06".
- Raxibacumab atcSuffix "BB18".
- Raxibacumab c "6320".
- Raxibacumab casNumber "565451".
- Raxibacumab chemspiderid "none".
- Raxibacumab h "9794".
- Raxibacumab mabType "mab".
- Raxibacumab molecularWeight "142.93".
- Raxibacumab n "1702".
- Raxibacumab o "1998".
- Raxibacumab s "42".
- Raxibacumab source "u".
- Raxibacumab target "Protective antigen of anthrax toxin".
- Raxibacumab type "mab".
- Raxibacumab verifiedfields "changed".
- Raxibacumab verifiedrevid "464380354".
- Raxibacumab watchedfields "changed".
- Raxibacumab wikiPageUsesTemplate Template:Antiinfective-drug-stub.
- Raxibacumab wikiPageUsesTemplate Template:Cascite.
- Raxibacumab wikiPageUsesTemplate Template:Chemspidercite.
- Raxibacumab wikiPageUsesTemplate Template:Drugbankcite.
- Raxibacumab wikiPageUsesTemplate Template:Drugbox.
- Raxibacumab wikiPageUsesTemplate Template:Immune_sera_and_immunoglobulins.
- Raxibacumab wikiPageUsesTemplate Template:Monoclonals_for_infectious_disease_and_toxins.
- Raxibacumab wikiPageUsesTemplate Template:Reflist.
- Raxibacumab subject Category:Monoclonal_antibodies.
- Raxibacumab hypernym Antibody.
- Raxibacumab type ChemicalSubstance.
- Raxibacumab type Drug.
- Raxibacumab type Antibody.
- Raxibacumab type Chemical.
- Raxibacumab type Drug.
- Raxibacumab type ChemicalObject.
- Raxibacumab type Thing.
- Raxibacumab type Q8386.
- Raxibacumab comment "Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys.".
- Raxibacumab label "Raxibacumab".
- Raxibacumab sameAs Q7297093.
- Raxibacumab sameAs m.02ppljs.
- Raxibacumab sameAs Raksibakumab.
- Raxibacumab sameAs Raksibakumab.
- Raxibacumab sameAs Q7297093.
- Raxibacumab wasDerivedFrom Raxibacumab?oldid=707386024.
- Raxibacumab isPrimaryTopicOf Raxibacumab.